Advancing SION-451 + SION-2222 dual combination to AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in the first quarter of 2027
Clinical and nonclinical data presented at 2026 NACFC support advancement of SION-451 + SION-2222 and the potential of NBD1 stabilizer combinations to benefit a broad population of people with CF
Strong cash position of $249.8 million as of September 30, 2026, expected to fund operations into the second half of 2029
WALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to develop novel medicines for cystic fibrosis (CF), today reported financial results for the third quarter ended September 30, 2026, and provided a business update.
"During the third quarter, we established a focused path forward for Sionna centered on SION-451 + SION-2222, our proprietary, NBD1-anchored dual combination," said Mike Cloonan, President and Chief Executive Officer of Sionna. "We believe the findings from the PreciSION CF post hoc analyses, together with the dual combination's favorable Phase 1 results, support advancing the dual combination into the next phase of development. With our resources focused on developing this program and cash runway expected into the second half of 2029, we are well-positioned to execute our strategy to deliver new treatment options for people with CF."
Pipeline Updates
-- SION-451 + SION-2222 Dual Combination Advancing into AscenSION CF Phase 2
proof-of-concept: Sionna plans to initiate the AscenSION CF Phase 2
proof-of-concept (POC) trial in the first quarter of 2027. SION-451 is an
NBD1 stabilizer and SION-2222 (galicaftor) is a transmembrane domain 1
(TMD1)-directed CFTR corrector. The open-label trial will evaluate
participants with CF homozygous for F508del treated with SION-451 +
SION-2222 for 28 days after switching from Trikafta(R). The trial will
assess sweat chloride, safety, and pharmacokinetics (PK), and its design
will incorporate key learnings from PreciSION CF related to dosing
adherence and sweat chloride variability. SION-451 + SION-2222 was
selected as the dual combination based on the totality of the clinical,
PK, and nonclinical data, including achievement of the safety,
tolerability, and PK objectives in the Phase 1 healthy volunteer trial.
-- Completed Comprehensive Analysis of SION-719 PreciSION CF: As previously
announced, the PreciSION CF Phase 2a trial of SION-719 added to Trikafta
did not achieve its key activity endpoint, and Sionna is not advancing
SION-719 as an add-on to standard of care. Post hoc analyses excluding
three participants with drug exposures consistent with dosing
non-adherence showed a mean placebo-adjusted sweat chloride reduction of
up to -8.6 mmol/L when SION-719 was added to Trikafta, which Sionna
believes is indicative of NBD1 biological activity. The analyses also
identified other potential confounding factors related to the complex
interaction of SION-719 combined with Trikafta that may have blunted the
additional benefit of NBD1 stabilization. These findings, together with
results from the Phase 1 dual combination trial, informed the decision to
advance SION-451 + SION-2222 and the design of the AscenSION CF trial.
-- Presented Clinical and Nonclinical Data at 2026 North American Cystic
Fibrosis Conference: In October 2026, Sionna presented clinical and
nonclinical data in an oral presentation and poster at the North American
Cystic Fibrosis Conference (NACFC) in Atlanta, Georgia. The oral
presentation summarized the previously disclosed post hoc analyses of
PreciSION CF and the rationale for advancing SION-451 + SION-2222 into
AscenSION CF. The poster evaluated the effects of Sionna's NBD1
stabilizers, SION-451 and SION-719, in combination with complementary
CFTR modulators, including SION-2222 and SION-109, in primary CF human
bronchial epithelial cells from donors with either two copies of F508del
or one copy of F508del and a null CFTR mutation. Across both donor groups,
the NBD1 stabilizer-based combinations demonstrated improved CFTR
trafficking and function up to wild-type levels, supporting their
potential to benefit a broad population of people with CF.
Corporate Update
-- Implemented Workforce Reduction and Cost-Saving Measures: In September
2026, following a comprehensive review of its operations, Sionna
implemented a workforce reduction of approximately 46% and other
cost-saving measures to focus resources on advancing SION-451 + SION-2222
and extend its operating runway.
Financial Results for the Quarter Ended September 30, 2026
Research and Development Expenses: Research and development expenses were $22.0 million for the third quarter of 2026, compared to $16.0 million for the third quarter of 2025. This increase was primarily driven by development expenses incurred during the period, personnel-related costs, including stock-based compensation expenses, and restructuring related costs associated with the workforce reduction.
General and Administrative Expenses: General and administrative expenses were $12.8 million for the third quarter of 2026, compared to $7.8 million for the third quarter of 2025. This increase was primarily due to personnel-related costs, including stock-based compensation expenses, and restructuring related costs associated with the workforce reduction.
Net Loss: Net loss was $32.4 million for the third quarter of 2026, compared to a net loss of $20.3 million for the third quarter of 2025.
Cash and Cash Equivalents: Cash, cash equivalents and marketable securities totaled $249.8 million as of September 30, 2026. Sionna expects its current cash position to fund operations into the second half of 2029.
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that improve the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna's goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR's nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking meaningful improvements in clinical outcomes and quality of life for people with CF. For more information about Sionna, visit www.sionnatx.com.
Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Sionna's Investor Relations website, in addition to following Sionna's press releases, SEC filings, public conference calls, presentations, and webcasts.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Sionna's beliefs and expectations regarding: its goal of transforming the treatment paradigm for CF and providing clinically meaningful benefit for people with CF; the potential of Sionna's product candidates, including the SION-451 + SION-2222 dual combination, to expand therapeutic options for people with CF, including the potential of NBD1 stabilizer combinations to benefit a broad population of people with CF; Sionna's interpretation of the results of the PreciSION CF trial and the impact of potential confounding factors on the interpretation of those results; the potential for NBD1 stabilization to improve CFTR function and produce clinical benefit, including beliefs about NBD1 biological activity in PreciSION CF and the translatability of preclinical and in vitro assay data to clinical outcomes; the objectives, design, timing, initiation and conduct of the AscenSION CF Phase 2 proof-of-concept trial of SION-451 + SION-2222; the therapeutic potential, clinical benefits and safety of SION-451 + SION-2222; the ability of clinical trials to demonstrate safety and efficacy of Sionna's product candidates; the ability of Sionna's nonclinical studies or earlier clinical trials, including post hoc analyses of the PreciSION CF trial, to predict later clinical trial results; the expected benefits of Sionna's workforce reduction and other cost-saving measures, including the ability to focus resources on advancing SION-451 + SION-2222 and to extend its operating runway; and financial projections and expectations regarding the time period in which Sionna's capital resources will be sufficient to fund its anticipated operations, including cash runway, use of capital, expenses and other financial results. In some cases, the forward-looking statements can be identified by terms such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties inherent in the development of product candidates, including uncertainties concerning the initiation, timing, progress, and results of Sionna's ongoing, planned and future clinical trials and studies;
Comments